The sponsor sends a copy of the six-monthly report mentioned in the previous paragraph to the Director General of the Agence nationale de sécurité du médicament et des produits de santé and, for information, to the Director General of the Agence de la biomédecine.
Once a year, the Committee for the Protection of Individuals receives the safety report referred to in Article R. 1123-53.

